Immune Therapy For Triple Negative Patients

Transcript

In triple negative breast cancer, where all of your receptors are negative, the HER2 is negative and your hormone receptors, estrogen and progesterone are negative.

If you are having neoadjuvant therapy, which means, let’s shrink this tumor as much as possible before we cut it out in hopes of cure, there has been an approval in July of 2021 that showed a significant improvement in relapse as well as survival to add immune therapy called pembrolizumab to the chemotherapy during that neoadjuvant or pre-surgery phase, as well as after the surgery to continue to give that pembrolizumab.

The data showed that this both improves progression-free survival as well as overall survival.

Key Takeaways

1. Triple negative breast cancer is where all of your receptors are negative.

2. If you are having neoadjuvant therapy, there was an approval in July of 2021 to add an immune therapy called pembrolizumab to the chemotherapy before or after surgery.

3. The data showed that this both improves progression-free survival as well as overall survival.